SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4636-4642. Prepublished online as a Blood First Edition Paper on February 14, 2006; DOI 10.1182/blood-2005-11-4429. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-11-4429v1 107/12/4636    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fermé, C. Articles by Gisselbrecht, C. Search for Related Content PubMed PubMed Citation Articles by Fermé, C. Articles by Gisselbrecht, C. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Christophe Fermé, Nicolas Mounier, Olivier Casasnovas, Pauline Brice, Marine Divine, Anne Sonet, Fahdela Bouafia, Aspasia Bastard-Stamatoullas, Dominique Bordessoule, Laurent Voillat, Oumedaly Reman, Michel Blanc, Christian Gisselbrecht, for the Groupe d'Etude des Lymphomes de l'Adulte From the Department of Medicine, Institut Gustave Roussy, Villejuif Cedex, France; Hopital Saint-Louis, Paris, France; Centre Hospitalier Universitaire (CHU) de Dijon, Dijon, France; CHU Henri Mondor, Creteil, France; Universite Catholique de Louvain, Yvoir, Belgium; Hospices Civils de Lyon, Pierre-Benite, France; Centre Becquerel, Rouen, France; CHU de Limoges, Limoges, France; CHU de Besancon, Besancon, France; CHU de Caen, Caen, France; and Centre Hospitalier de Chambery, Chambery, France. From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine; n = 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone; n = 267). Patients in complete remission (CR) or partial response of at least 75% after 6 cycles received 2 cycles of consolidation chemotherapy (CT) (n = 208) or subtotal nodal irradiation (RT) (n = 210). A better survival probability was observed after ABVPP alone: the 10-year overall survival (OS) estimates were 90% for ABVPPx8, 78% for MOPP/ABVx8, 82% for MOPP/ABV with RT, and 77% for ABVPPx6 with RT (P = .03); and the 10-year disease-free survival (DFS) estimates were 70%, 76%, 79%, and 76%, respectively (P = .09). The 10-year DFS estimates for patients treated with consolidation CT or RT were 73% and 78% (P = .07), and OS estimates were 84% and 79%, respectively (P = .29). These results showed that RT was not superior to consolidation CT after a doxorubicin-induced CR in patients with advanced HL. An analysis of competing risks identified age more than 45 years as a significant risk factor for death, relapse, and second cancers. Prospective evaluation of late adverse events may improve the management of patients with HL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: I. Biasoli, P. Franchi-Rezgui, D. Sibon, J. Briere, E. de Kerviler, C. Thieblemont, V. Levy, C. Gisselbrecht, and P. Brice Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy Ann. Onc., June 13, 2008; (2008) mdn391v1. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020